Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide EAP for Chinese Patients with RRMM
NCT02348528Phase 2
Key facts
- Status
- Completed
- Start
- Sep 2012
- Primary completion
- Sep 2016
- Countries
- 1
- Sponsor
- Celgene Corporation
- Modality
- Small Molecules
- Drugs
- lenalidomide
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Adverse Events at 4 years. Started Sep 2012; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Lenalidomide + Dexamethasone
Continuation of Rd regimen from previous study.
03
Who it enrols
Chinese subjects with relapsed/refractory multiple myeloma who completed at least 1 year of treatment in study CC-5013-MM-021 and remained progression-free.
04
Endpoints
Primary
Adverse Events
Secondary
Progression Free Survival
Time to Progression
Overall Survival
Beyond the preview
Go deeper on NCT02348528.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348528.